Accumulating evidences have stated that Aβ, p-tau, and t-tau in CSF are well performed as disease progression markers [49, 50], while the diagnostic potential of sTREM2 as a biomarker of microglial cell activity in early Alzheimer's disease was also described [47], similar with MS [2]. The gene discussed is MAPT; the disease is Alzheimer disease.